brigimadlin

Brigimadlin is an orally available, highly potent small molecule inhibitor of murine double minute 2 (MDM2), developed as an antineoplastic agent. It functions as a MDM2–p53 antagonist, binding to the MDM2 protein and preventing its interaction with the tumor suppressor protein p53. This blockade restores p53 activity, leading to cell-cycle arrest and apoptosis in TP53 wild-type tumors. Brigimadlin has shown encouraging antitumor activity in early-phase clinical trials, particularly in patients with advanced or metastatic solid tumors that are MDM2-amplified, such as well-differentiated or dedifferentiated liposarcoma and biliary tract cancers. The drug is being investigated both as monotherapy and in combination regimens for various cancer types[1][2][5][7].

Brand names

brigimadlin

Other names

BI907828BI-907828BI 907828